191 results on '"Mauer, Murielle"'
Search Results
2. Comparing methods addressing multi-collinearity when developing prediction models
3. EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need
4. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
5. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
6. Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey
7. Performance of binary prediction models in high-correlation low-dimensional settings: a comparison of methods
8. Improving Clinical Trial Design in Gastrointestinal Oncology
9. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review
10. Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program
11. Cancer events in Belgian nursing home residents: An EORTC prospective cohort study
12. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study
13. Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
14. Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study.
15. Health-Related Quality of Life Studies in International Randomized Controlled Oncology Clinical Trials
16. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
17. Response
18. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG
19. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
20. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
21. EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
22. Additional file 1 of Performance of binary prediction models in high-correlation low-dimensional settings: a comparison of methods
23. Additional file 5 of Performance of binary prediction models in high-correlation low-dimensional settings: a comparison of methods
24. Additional file 3 of Performance of binary prediction models in high-correlation low-dimensional settings: a comparison of methods
25. Additional file 6 of Performance of binary prediction models in high-correlation low-dimensional settings: a comparison of methods
26. Additional file 2 of Performance of binary prediction models in high-correlation low-dimensional settings: a comparison of methods
27. Additional file 4 of Performance of binary prediction models in high-correlation low-dimensional settings: a comparison of methods
28. The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management
29. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis.
30. Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases
31. CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset
32. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials
33. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.
34. EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study.
35. Reply to P. Potemski and K. Bujko
36. Duration of androgen suppression in the treatment of prostrate cancer
37. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
38. Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.
39. EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.
40. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
41. Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer
42. Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative
43. Sample size computation in phase II designs combining the A’Hern design and the Sargent and Goldberg design
44. Inappropriate Grading of Adverse Events in Cancer Clinical Trials—Reply
45. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
46. Association of Patient Sex With Chemotherapy-Related Toxic Effects
47. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.
48. EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB).
49. Cancer events in Belgian nursing home residents (NHR): An EORTC prospective cohort study.
50. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.